Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer
Cortés J., Rodríguez J., Calvo E., Gúrpide A., García-Foncillas J., Salgado E., Aramendía J.M., López-Picazo J.M., Hernández B., Hidalgo R., Aristu J.J., Brugarolas A., Martín-Algarra S.
Department of Oncology, Clínica Universitaria de Navarra, Pamplona, Spain.
Magazine: American Journal of Clinical Oncology
Date: Jun 1, 2004Radiation Oncology Medical Oncology
Vinorelbine-cisplatin combination chemotherapy is a standard approach for the treatment of advanced non-small-cell lung cancer (NSCLC). The addition of paclitaxel as a third therapeutic agent seems promising.
The aim of the present study was to evaluate the activity and toxicity of this new regimen. Forty-six nonselected and chemotherapy-naive patients with stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0 to 2 were treated every 4 weeks with paclitaxel (135 mg/m2 given iv in 3 hours) and cisplatin (120 mg/m2 given iv in 6 hours) on day 1 and vinorelbine (30 mg/m2 given iv in 30 minutes) on days 1 and 15. All patients were evaluated for toxicity and response according to the intent-to-treat principle. An objective response was observed in 39% of the patients (95% CI: 25% to 55%). World Health Organization grade III to IV neutropenia, thrombocytopenia, and anemia occurred in 43%, 2%, and 17%, respectively.
There was one treatment-related death. Nonhematologic toxicities were mild, mainly grade III nausea and vomiting in 20% of the patients. After a median follow-up period of 54 months, the median progression-free survival was 14.3 weeks and the median overall survival was 31.3 weeks. This three-drug chemotherapy combination is feasible, well tolerated, and shows activity in metastatic NSCLC.
CITATION Am J Clin Oncol. 2004 Jun;27(3):299-303
you maybe interested
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.